Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

被引：0

作者：

Moskowitz, Alison J. ^{[1
]}

Shah, Gunjan ^{[2
]}

Schoder, Heiko ^{[1
]}

Ganesan, Nivetha ^{[1
]}

Hancock, Helen ^{[1
]}

Davey, Theresa ^{[1
]}

Sohail, Samia ^{[1
]}

Santarosa, Alayna ^{[1
]}

Pomerantz, Lauren ^{[1
]}

Jarjies, Christine ^{[1
]}

Galasso, Natasha ^{[1
]}

Neuman, Rachel ^{[1
]}

Kumar, Anita ^{[1
]}

Lahoud, Oscar B. ^{[3
]}

Batlevi, Connie Lee ^{[1
]}

Hamlin, Paul A. ^{[1
]}

Straus, David J. ^{[1
]}

Rodriguez-Rivera, Ildefonso ^{[1
]}

Owens, Colette ^{[1
]}

Caron, Philip ^{[1
]}

Intlekofer, Andrew M. ^{[1
]}

Hamilton, Audrey ^{[1
]}

Horwitz, Steven M. ^{[1
]}

Falchi, Lorenzo ^{[1
]}

Joffe, Erel ^{[1
]}

Palomba, Maria Lia ^{[1
]}

Noy, Ariela ^{[4
]}

Matasar, Matthew J. ^{[1
]}

Pongas, Georgios ^{[5
]}

Vardhana, Santosha ^{[1
]}

von Keudell, Gottfried R. ^{[1
]}

Yahalom, Joachim ^{[1
]}

Zelenetz, Andrew D. ^{[1
]}

Moskowitz, Craig H. ^{[5
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, Brooklyn, NY USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[5] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

来源：

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 03期

关键词：

STEM-CELL TRANSPLANTATION; PET;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The international phase 2 CAPTIVATE (PCYC-1142) study evaluated ibrutinib (420 mg daily) plus venetoclax (ramped up to 400 mg daily) as first-line therapy in patients with CLL (Abstract 123). After 12 cycles of treatment, patients with confirmed undetectable MRD were randomly assigned in a double-blind manner to receive ibrutinib or placebo, and those with detectable MRD or unconfirmed undetectable MRD were randomly assigned to receive open-label ibrutinib monotherapy or ibrutinib plus venetoclax. The median age of the 164 patients was 58 years (range, 28-69), and the majority had at least 1 high-risk genetic feature. Among the patients with confirmed undetectable MRD before randomization, the rate of disease-free survival at 1 year after randomization was 100.0% in the ibrutinib group vs 95.3% in the placebo group (P=.1475). Across all 4 randomized cohorts, the 30-month PFS was between 95% and 100%. No new safety signals arose.

引用

页码：14 / 15

页数：2

共 50 条

[1] Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
Moskowitz, Alison J.
Shah, Gunjan
Schoder, Heiko
Ganesan, Nivetha
Hancock, Helen
Davey, Theresa
Sohail, Samia
Santarosa, Alayna
Pomerantz, Lauren
Jarjies, Christine
Galasso, Natasha
Neuman, Rachel
Kumar, Anita
Lahoud, Oscar B.
Batlevi, Connie Lee
Hamlin, Paul A.
Straus, David J.
Rodriguez-Rivera, Ildefonso
Owens, Colette
Caron, Philip
Intlekofer, Andrew M.
Hamilton, Audrey
Horwitz, Steven M.
Falchi, Lorenzo
Joffe, Erel
Palomba, Maria Lia
Noy, Ariela
Matasar, Matthew J.
Pongas, Georgios
Vardhana, Santosha
von Keudell, Gottfried R.
Yahalom, Joachim
Zelenetz, Andrew D.
Moskowitz, Craig H.
[J]. BLOOD, 2020, 136
[2] Phase II Study of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
不详
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 10 - 11
[3] Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
Moskowitz, Alison J.
Shah, Gunjan
Schoeder, Heiko
Ganesan, Nivetha
Drill, Esther
Hancock, Helen
Davey, Theresa
Perez, Leslie
Ryu, Sunyoung
Sohail, Samia
Santarosa, Alayna
Galasso, Natasha
Neuman, Rachel
Liotta, Brielle
Blouin, William
Kumar, Anita
Lahoud, Oscar
Batlevi, Connie L.
Hamlin, Paul
Straus, David J.
Rodriguez-Rivera, Ildefonso
Owens, Colette
Caron, Philip
Intlekofer, Andrew M.
Hamilton, Audrey
Horwitz, Steven M.
Falchi, Lorenzo
Joffe, Erel
Johnson, William
Lee, Christina
Palomba, M. Lia
Noy, Ariela
Matasar, Matthew J.
Pongas, Georgios
Salles, Gilles
Vardhana, Santosha
Sanin, Beatriz Wills
von Keudell, Gottfried
Yahalom, Joachim
Dogan, Ahmet
Zelenetz, Andrew D.
Moskowitz, Craig H.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28) : 3109 - +
[4] Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
Wills, Beatriz
Ganesan, Nivetha
Shah, Gunjan L.
Wong, Phillip
Argyropoulos, Kimon, V
Sen, Filiz
Dogan, Ahmet
Straus, David J.
Noy, Ariela
Kumar, Anita
Schoder, Heiko
Michaud, Laure
Palomba, Maria Lia
Falchi, Lorenzo
Lahoud, Oscar B.
Hamlin, Paul A.
Yahalom, Joachim
Johnson, William T.
Zelenetz, Andrew D.
Intlekofer, Andrew M.
Owens, Colette
Batlevi, Connie Lee
Hamilton, Audrey
Caron, Philip C.
Horwitz, Steven M.
Galasso, Natasha
Hancock, Helen
Davey, Theresa
Santarosa, Alayna
Perez, Leslie
Capadona, Charisse
Munayirji, Brittney
Matasar, Matthew J.
Pongas, Georgios
Casper, Ellie
Salles, Gilles
Moskowitz, Craig H.
Vardhana, Santosha
Moskowitz, Alison J.
[J]. BLOOD, 2022, 140 : 9286 - 9288
[5] Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma
Zhang, Yu-Chen
Wang, Jin-Ni
Ma, Shu-Yun
Cai, Jun
Su, Ning
Huang, Hui-Qiang
Li, Zhi-Ming
Xia, Zhong-Jun
Huang, He
Liu, Pan-Pan
Xia, Yi
Cai, Qing-Qing
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (01) : 127 - 135
[6] High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma
Moskowitz, Alison J.
Shah, Gunjan L.
Schoder, Heiko
Hancock, Helen
Davey, Theresa
Joong, Christopher
Pomerantz, Lauren
Jarjies, Christine
Kumar, Anita
Lahoud, Oscar B.
Batlevi, Connie Lee
Hamlin, Paul A.
Straus, David J.
Rodriguez-Rivera, Ildefonso
Owens, Colette
Caron, Philip
Colbourn, Donald Steven
Intlekofer, Andrew M.
Hamilton, Audrey
Horwitz, Steven M.
Joffe, Erel
Palomba, M. Lia
Noy, Ariela
Matasar, Matthew J.
Vardhana, Santosha
von Keudell, Gottfried R.
Yahalom, Joachim
Younes, Anas
Zelenetz, Andrew D.
Moskowitz, Craig H.
[J]. BLOOD, 2019, 134
[7] Pembrolizumab and allotransplants for relapsed refractory classical hodgkin lymphoma
Halahleh, K.
Muradi, I.
Al-Rimawi, D.
Ma'koseh, M.
[J]. BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 203 - 204
[8] Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Chen, Robert
Zinzani, Pier Luigi
Fanale, Michelle A.
Armand, Philippe
Johnson, Nathalie A.
Brice, Pauline
Radford, John
Ribrag, Vincent
Molin, Daniel
Vassilakopoulos, Theodoros P.
Tomita, Akihiro
von Tresckow, Bastian
Shipp, Margaret A.
Zhang, Yinghua
Ricart, Alejandro D.
Balakumaran, Arun
Moskowitz, Craig H.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2125 - +
[9] Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma
Chen, Robert
Palmer, Joycelynne M.
Martin, Peter
Tsai, Nicole
Kim, Young
Chen, Bihong T.
Popplewell, Leslie
Siddiqi, Tanya
Thomas, Sandra H.
Mott, Michelle
Sahebi, Firoozeh
Armenian, Saro
Leonard, John
Nademanee, Auayporn
Forman, Stephen J.
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (12) : 2136 - 2140
[10] Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
Liu, Yanfei
Ping, Lingyan
Song, Yuqin
Tang, Yongjing
Zheng, Wen
Liu, Weiping
Ying, Zhitao
Zhang, Chen
Wu, Meng
Feng, Feier
Lin, Ningjing
Tu, Meifeng
Zhu, Jun
Xie, Yan
[J]. BMC MEDICINE, 2024, 22 (01)

← 1 2 3 4 5 →